BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: De Cicco P, Ercolano G, Ianaro A. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion. Front Immunol 2020;11:1680. [PMID: 32849585 DOI: 10.3389/fimmu.2020.01680] [Cited by in Crossref: 88] [Cited by in F6Publishing: 96] [Article Influence: 29.3] [Reference Citation Analysis]
Number Citing Articles
1 Wang S, Zhao X, Wu S, Cui D, Xu Z. Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies. Biomark Res 2023;11:34. [PMID: 36978204 DOI: 10.1186/s40364-023-00475-8] [Reference Citation Analysis]
2 Hess NJ, Kink JA, Hematti P. Exosomes, MDSCs and Tregs: A new frontier for GVHD prevention and treatment. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1143381] [Reference Citation Analysis]
3 Liu S, Liao Y, Chen Y, Yang H, Hu Y, Chen Z, Fu S, Wu J. Effect of triple therapy with low-dose total body irradiation and hypo-fractionated radiation plus anti-programmed cell death protein 1 blockade on abscopal antitumor immune responses in breast cancer. Int Immunopharmacol 2023;117:110026. [PMID: 36934673 DOI: 10.1016/j.intimp.2023.110026] [Reference Citation Analysis]
4 Tang C, Sun H, Kadoki M, Han W, Ye X, Makusheva Y, Deng J, Feng B, Qiu D, Tan Y, Wang X, Guo Z, Huang C, Peng S, Chen M, Adachi Y, Ohno N, Trombetta S, Iwakura Y. Blocking Dectin-1 prevents colorectal tumorigenesis by suppressing prostaglandin E2 production in myeloid-derived suppressor cells and enhancing IL-22 binding protein expression. Nat Commun 2023;14:1493. [PMID: 36932082 DOI: 10.1038/s41467-023-37229-x] [Reference Citation Analysis]
5 Sánchez-león ML, Jiménez-cortegana C, Silva Romeiro S, Garnacho C, de la Cruz-merino L, García-domínguez DJ, Hontecillas-prieto L, Sánchez-margalet V. Defining the Emergence of New Immunotherapy Approaches in Breast Cancer: Role of Myeloid-Derived Suppressor Cells. IJMS 2023;24:5208. [DOI: 10.3390/ijms24065208] [Reference Citation Analysis]
6 Starska-kowarska K. The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancer—Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy. Cancers 2023;15:1642. [DOI: 10.3390/cancers15061642] [Reference Citation Analysis]
7 Walsh MJ, Stump CT, Kureshi R, Lenehan P, Ali LR, Dougan M, Knipe DM, Dougan SK. IFNγ is a central node of cancer immune equilibrium. Cell Rep 2023;42:112219. [PMID: 36881506 DOI: 10.1016/j.celrep.2023.112219] [Reference Citation Analysis]
8 Canella A, Rajappa P. Therapeutic utility of engineered myeloid cells in the tumor microenvironment. Cancer Gene Ther 2023. [PMID: 36854896 DOI: 10.1038/s41417-023-00600-7] [Reference Citation Analysis]
9 Varela VA, da Silva Heinen LB, Marti LC, Caraciolo VB, Datoguia TS, Amano MT, Pereira WO. In vitro differentiation of myeloid suppressor cells (MDSC-like) from an immature myelomonocytic precursor THP-1. J Immunol Methods 2023;515:113441. [PMID: 36848984 DOI: 10.1016/j.jim.2023.113441] [Reference Citation Analysis]
10 Moliner L, Spurgeon L, Califano R. Controversies in NSCLC: which second-line strategy after chemo-immunotherapy? ESMO Open 2023;8:100879. [PMID: 36791668 DOI: 10.1016/j.esmoop.2023.100879] [Reference Citation Analysis]
11 Zhou L, Yang XQ, Zhao GY, Wang FJ, Liu X. Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer. Front Immunol 2023;14:1044353. [PMID: 36776899 DOI: 10.3389/fimmu.2023.1044353] [Reference Citation Analysis]
12 Molchanov OE, Maistrenko DN, Granov DA, Lisitsin IY, Romanov AA. Features of the microenvironment of oncourological tumors. Urology reports (St - Petersburg) 2023;12:313-331. [DOI: 10.17816/uroved112576] [Reference Citation Analysis]
13 Eid RA, Eldeen MA, Soltan MA, Al-Shraim M, Aldehri M, Alqahtani LS, Alsharif G, Albogami S, Jafri I, Fayad E, Park MN, Bibi S, Behairy MY, Kim B, Zaki MSA. Integrative analysis of WDR12 as a potential prognostic and immunological biomarker in multiple human tumors. Front Genet 2022;13:1008502. [PMID: 36726716 DOI: 10.3389/fgene.2022.1008502] [Reference Citation Analysis]
14 Meng S, Whitt AG, Stamp BF, Eaton JW, Li C, Yaddanapudi K. Exosome-based cancer vaccine for prevention of lung cancer. Stem Cell Investig 2023;10:2. [PMID: 36742283 DOI: 10.21037/sci-2022-030] [Reference Citation Analysis]
15 Singh KB, Hahm ER, Kim SH, Singh SV. Withaferin A Inhibits Fatty Acid Synthesis in Rat Mammary Tumors. Cancer Prev Res (Phila) 2023;16:5-16. [PMID: 36251722 DOI: 10.1158/1940-6207.CAPR-22-0193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Wang GC, Zhou M, Zhang Y, Cai HM, Chiang ST, Chen Q, Han TZ, Li RX. Screening and identifying a novel M-MDSCs-related gene signature for predicting prognostic risk and immunotherapeutic responses in patients with lung adenocarcinoma. Front Genet 2022;13:989141. [PMID: 36699465 DOI: 10.3389/fgene.2022.989141] [Reference Citation Analysis]
17 Borgna E, Prochetto E, Gamba JC, Marcipar I, Cabrera G. Role of myeloid-derived suppressor cells during Trypanosoma cruzi infection. International Review of Cell and Molecular Biology 2023. [DOI: 10.1016/bs.ircmb.2022.09.002] [Reference Citation Analysis]
18 Esmaeilzadeh A, Jafari D, Ghaebi M, Elahi R, Afshari F, Karimi L. Immune Gene Therapy of Cancer. Handbook of Cancer and Immunology 2023. [DOI: 10.1007/978-3-030-80962-1_202-1] [Reference Citation Analysis]
19 Liu Y, Han Y, Zhang Y, Lv T, Peng X, Huang J. LncRNAs has been identified as regulators of Myeloid-derived suppressor cells in lung cancer. Front Immunol 2023;14:1067520. [PMID: 36817434 DOI: 10.3389/fimmu.2023.1067520] [Reference Citation Analysis]
20 Saghazadeh A, Rezaei N. Myeloid-Derived Suppressor Cells and Cancer Metastasis. Handbook of Cancer and Immunology 2023. [DOI: 10.1007/978-3-030-80962-1_68-1] [Reference Citation Analysis]
21 Tang Y, Zhou C, Li Q, Cheng X, Huang T, Li F, He L, Zhang B, Tu S. Targeting depletion of myeloid-derived suppressor cells potentiates PD-L1 blockade efficacy in gastric and colon cancers. OncoImmunology 2022;11:2131084. [DOI: 10.1080/2162402x.2022.2131084] [Reference Citation Analysis]
22 Welty NE, Gill SI. Cancer Immunotherapy Beyond Checkpoint Blockade: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol 2022;4:563-78. [PMID: 36636439 DOI: 10.1016/j.jaccao.2022.11.006] [Reference Citation Analysis]
23 Al-Saafeen BH, Al-Sbiei A, Bashir G, Mohamed YA, Masad RJ, Fernandez-Cabezudo MJ, Al-Ramadi BK. Attenuated Salmonella potentiate PD-L1 blockade immunotherapy in a preclinical model of colorectal cancer. Front Immunol 2022;13:1017780. [PMID: 36605208 DOI: 10.3389/fimmu.2022.1017780] [Reference Citation Analysis]
24 Peng P, Lou Y, Wang S, Wang J, Zhang Z, Du P, Zheng J, Liu P, Xu LX. Activated NK cells reprogram MDSCs via NKG2D-NKG2DL and IFN-γ to modulate antitumor T-cell response after cryo-thermal therapy. J Immunother Cancer 2022;10. [PMID: 36521929 DOI: 10.1136/jitc-2022-005769] [Reference Citation Analysis]
25 Zheng L, Zhang L, Guo Y, Xu X, Liu Z, Yan Z, Fu R. The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome. Front Immunol 2022;13:1078421. [PMID: 36569863 DOI: 10.3389/fimmu.2022.1078421] [Reference Citation Analysis]
26 Liu Y, Xu C, Xiao X, Chen Y, Wang X, Liu W, Tan Y, Zhu W, Hu J, Liang J, Yan G, Lin Y, Cai J. Overcoming resistance to oncolytic virus M1 by targeting PI3K-γ in tumor-associated myeloid cells. Mol Ther 2022;30:3677-93. [PMID: 35552024 DOI: 10.1016/j.ymthe.2022.05.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Xiao T, Sun M, Chang Y, Kang J, Zhao C, Zhu R, Chen H, Qiang Y. Butyrate impeded the conscription of MDSCs to reduce CAC formation by blocking the TLR2 signaling pathway. Journal of Functional Foods 2022;99:105344. [DOI: 10.1016/j.jff.2022.105344] [Reference Citation Analysis]
28 Zhang X, Zhao L, Zhang H, Zhang Y, Ju H, Wang X, Ren H, Zhu X, Dong Y. The immunosuppressive microenvironment and immunotherapy in human glioblastoma. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1003651] [Reference Citation Analysis]
29 Shibata M, Nanno K, Yoshimori D, Nakajima T, Takada M, Yazawa T, Mimura K, Inoue N, Watanabe T, Tachibana K, Muto S, Momma T, Suzuki Y, Kono K, Endo S, Takenoshita S. Myeloid-derived suppressor cells: Cancer, autoimmune diseases, and more. Oncotarget 2022;13:1273-85. [PMID: 36395389 DOI: 10.18632/oncotarget.28303] [Reference Citation Analysis]
30 Bayik D, Bartels CF, Lovrenert K, Watson DC, Zhang D, Kay K, Lee J, Lauko A, Johnson S, Lo A, Silver DJ, McGraw M, Grabowski M, Mohammadi AM, Veglia F, Fan Y, Vogelbaum MA, Scacheri P, Lathia JD. Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets. Cancer Res 2022;82:4274-87. [PMID: 36126163 DOI: 10.1158/0008-5472.CAN-21-3840] [Reference Citation Analysis]
31 Ahmed YB, Al-Bzour AN, Ababneh OE, Abushukair HM, Saeed A. Genomic and Transcriptomic Predictors of Response to Immune Checkpoint Inhibitors in Melanoma Patients: A Machine Learning Approach. Cancers (Basel) 2022;14. [PMID: 36428698 DOI: 10.3390/cancers14225605] [Reference Citation Analysis]
32 Yue Lou, Peng Peng, Shicheng Wang, Junjun Wang, Peishan Du, Zelu Zhang, Jiamin Zheng, Ping Liu, Lisa X. Xu. Combining all-trans retinoid acid treatment targeting myeloid-derived suppressive cells with cryo-thermal therapy enhances antitumor immunity in breast cancer. Front Immunol 2022;13:1016776. [PMID: 36389684 DOI: 10.3389/fimmu.2022.1016776] [Reference Citation Analysis]
33 Xia Y, Yang R, Zhu J, Wang H, Li Y, Fan J, Fu C. Engineered nanomaterials trigger abscopal effect in immunotherapy of metastatic cancers. Front Bioeng Biotechnol 2022;10. [DOI: 10.3389/fbioe.2022.890257] [Reference Citation Analysis]
34 Lim YJ, Koh J, Choi M, Kim S, Chie EK. Prognostic stratification based on the levels of tumor-infiltrating myeloid-derived suppressor cells and PD-1/PD-L1 axis in locally advanced rectal cancer. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1018700] [Reference Citation Analysis]
35 Yang J, Xu Y, Xie K, Gao L, Zhong W, Liu X. CEBPB is associated with active tumor immune environment and favorable prognosis of metastatic skin cutaneous melanoma. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.991797] [Reference Citation Analysis]
36 Fan R, De Beule N, Maes A, De Bruyne E, Menu E, Vanderkerken K, Maes K, Breckpot K, De Veirman K. The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers. Front Immunol 2022;13:1016059. [DOI: 10.3389/fimmu.2022.1016059] [Reference Citation Analysis]
37 Yaping W, Zhe W, Zhuling C, Ruolei L, Pengyu F, Lili G, Cheng J, Bo Z, Liuyin L, Guangdong H, Yaoling W, Niuniu H, Rui L. The soldiers needed to be awakened: Tumor-infiltrating immune cells. Front Genet 2022;13:988703. [DOI: 10.3389/fgene.2022.988703] [Reference Citation Analysis]
38 Tong Y, Cao Y, Jin T, Huang Z, He Q, Mao M. Role of Interleukin-1 family in bone metastasis of prostate cancer. Front Oncol 2022;12:951167. [DOI: 10.3389/fonc.2022.951167] [Reference Citation Analysis]
39 Santiago-sánchez GS, Hodge JW, Fabian KP. Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation. Front Immunol 2022;13:993624. [DOI: 10.3389/fimmu.2022.993624] [Reference Citation Analysis]
40 Lau D, Corrie PG, Gallagher FA. MRI techniques for immunotherapy monitoring. J Immunother Cancer 2022;10:e004708. [PMID: 36122963 DOI: 10.1136/jitc-2022-004708] [Reference Citation Analysis]
41 Al-mterin MA, Elkord E. Myeloid-derived suppressor cells in colorectal cancer: prognostic biomarkers and therapeutic targets. Exploration of Targeted Anti-tumor Therapy 2022. [DOI: 10.37349/etat.2022.00097] [Reference Citation Analysis]
42 Spunde K, Korotkaja K, Zajakina A. Recombinant Viral Vectors for Therapeutic Programming of Tumour Microenvironment: Advantages and Limitations. Biomedicines 2022;10:2142. [DOI: 10.3390/biomedicines10092142] [Reference Citation Analysis]
43 Tang Y, Kwiatkowski DJ, Henske EP. Midkine expression by stem-like tumor cells drives persistence to mTOR inhibition and an immune-suppressive microenvironment. Nat Commun 2022;13:5018. [PMID: 36028490 DOI: 10.1038/s41467-022-32673-7] [Reference Citation Analysis]
44 Gianni C, Palleschi M, Schepisi G, Casadei C, Bleve S, Merloni F, Sirico M, Sarti S, Cecconetto L, Di Menna G, Schettini F, De Giorgi U. Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment. Front Oncol 2022;12:882896. [DOI: 10.3389/fonc.2022.882896] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Hong Y, Wen R, Wu G, Li S, Liu W, Chen Z, Yang Z. Abnormal immune function of MDSC and NK cells from chronic phase CML patients restores with tyrosine kinase inhibitors. International Immunopharmacology 2022;109:108821. [DOI: 10.1016/j.intimp.2022.108821] [Reference Citation Analysis]
46 Kousalová J, Šírová M, Kostka L, Šubr V, Kovářová J, Běhalová K, Studenovský M, Kovář M, Etrych T. Metastatic spread inhibition of cancer cells through stimuli-sensitive HPMA copolymer-bound actinonin nanomedicines. Nanomedicine: Nanotechnology, Biology and Medicine 2022;44:102578. [DOI: 10.1016/j.nano.2022.102578] [Reference Citation Analysis]
47 Smith C, Zheng W, Dong J, Wang Y, Lai J, Liu X, Yin F. Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy. World J Gastroenterol 2022; 28(27): 3297-3313 [DOI: 10.3748/wjg.v28.i27.3297] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Reckamp KL, Redman MW, Dragnev KH, Minichiello K, Villaruz LC, Faller B, Al Baghdadi T, Hines S, Everhart L, Highleyman L, Papadimitrakopoulou V, Neal JW, Waqar SN, Patel JD, Gray JE, Gandara DR, Kelly K, Herbst RS. Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A. J Clin Oncol 2022;40:2295-306. [PMID: 35658002 DOI: 10.1200/JCO.22.00912] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 17.0] [Reference Citation Analysis]
49 Benguigui M, Vorontsova A, Timaner M, Levin S, Haj-shomaly J, Deo A, Menachem R, Manobla B, Cooper TJ, Raviv Z, Shaked Y. Bv8 Blockade Sensitizes Anti-PD1 Therapy Resistant Tumors. Front Immunol 2022;13:903591. [DOI: 10.3389/fimmu.2022.903591] [Reference Citation Analysis]
50 Giurini EF, Williams M, Morin A, Zloza A, Gupta KH. Inactivated SARS-CoV-2 Reprograms the Tumor Immune Microenvironment and Improves Murine Cancer Outcomes.. [DOI: 10.1101/2022.06.30.498305] [Reference Citation Analysis]
51 Hughes DJ, Subesinghe M, Taylor B, Bille A, Spicer J, Papa S, Goh V, Cook GJR. 18F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer. Radiology 2022;:212481. [PMID: 35762888 DOI: 10.1148/radiol.212481] [Reference Citation Analysis]
52 Nguyen DT, Ogando-Rivas E, Liu R, Wang T, Rubin J, Jin L, Tao H, Sawyer WW, Mendez-Gomez HR, Cascio M, Mitchell DA, Huang J, Sawyer WG, Sayour EJ, Castillo P. CAR T Cell Locomotion in Solid Tumor Microenvironment. Cells 2022;11. [PMID: 35741103 DOI: 10.3390/cells11121974] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Kreger J, Roussos Torres ET, Maclean AL. Myeloid-derived suppressor cell dynamics control outcomes in the metastatic niche.. [DOI: 10.1101/2022.06.15.496246] [Reference Citation Analysis]
54 Sajid M, Liu L, Sun C. The Dynamic Role of NK Cells in Liver Cancers: Role in HCC and HBV Associated HCC and Its Therapeutic Implications. Front Immunol 2022;13:887186. [PMID: 35669776 DOI: 10.3389/fimmu.2022.887186] [Reference Citation Analysis]
55 Chen H, Lu D, Yang X, Hu Z, He C, Li H, Lin Z, Yang M, Xu X. One Shoot, Two Birds: Alleviating Inflammation Caused by Ischemia/Reperfusion Injury to Reduce the Recurrence of Hepatocellular Carcinoma. Front Immunol 2022;13:879552. [PMID: 35634295 DOI: 10.3389/fimmu.2022.879552] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
56 Tang Y, Kwiatkowski DJ, Henske EP. Midkine expression by stem-like tumor cells drives persistence to mTOR inhibition and rewires the microenvironment toward an immune-suppressive state.. [DOI: 10.1101/2022.06.01.494055] [Reference Citation Analysis]
57 Rosalia B, Matteo B, Ester B, Giovanni Z, Daniela Claudia M, Pier Giulio C, Giuseppe E, Angela I. Tissue-Resident Innate Immune Cell-Based Therapy: A Cornerstone of Immunotherapy Strategies for Cancer Treatment. Front Cell Dev Biol 2022;10:907572. [DOI: 10.3389/fcell.2022.907572] [Reference Citation Analysis]
58 Ao Z, Wu Z, Cai H, Hu L, Li X, Kaurich C, Chang J, Gu M, Liang C, Lu X, Guo F. Rapid Profiling of Tumor-Immune Interaction Using Acoustically Assembled Patient-Derived Cell Clusters. Adv Sci (Weinh) 2022;:e2201478. [PMID: 35611994 DOI: 10.1002/advs.202201478] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
59 Kim SK, Cho SW. The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment. Front Pharmacol 2022;13:868695. [DOI: 10.3389/fphar.2022.868695] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
60 Luo W, Xiang W, Gan L, Che J, Li J, Wang Y, Han L, Gu R, Ye L, Wang R, Zhang X, Xu Y, Dai W, Mo S, Li Q, Cai G. Bulk and single-cell transcriptome profiling reveal necroptosis-based molecular classification, tumor microenvironment infiltration characterization, and prognosis prediction in colorectal cancer. J Transl Med 2022;20:235. [PMID: 35590418 DOI: 10.1186/s12967-022-03431-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Lu K, Chiu KY, Cheng CL. Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution. Cancer Treat Res 2022;183:201-23. [PMID: 35551661 DOI: 10.1007/978-3-030-96376-7_7] [Reference Citation Analysis]
62 Luo W, Napoleon JV, Zhang F, Lee YG, Wang B, Putt KS, Low PS. Repolarization of Tumor-Infiltrating Myeloid Cells for Augmentation of CAR T Cell Therapies. Front Immunol 2022;13:816761. [PMID: 35250995 DOI: 10.3389/fimmu.2022.816761] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
63 Qu X, Wang M, Wang M, Tang H, Zhang S, Yang H, Yuan W, Wang Y, Yang J, Yue B. Multi-Mode Antibacterial Strategies Enabled by Gene-Transfection and Immunomodulatory Nanoparticles in 3D-Printed Scaffolds for Synergistic Exogenous and Endogenous Treatment of Infections. Adv Mater 2022;34:e2200096. [PMID: 35267223 DOI: 10.1002/adma.202200096] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
64 Wang Y, Wang J, Zhu F, Wang H, Yi L, Huang K, Zhai Z. Elevated circulating myeloid-derived suppressor cells associated with poor prognosis in B-cell non-Hodgkin's lymphoma patients. Immun Inflamm Dis 2022;10:e616. [PMID: 35478441 DOI: 10.1002/iid3.616] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
65 Borges RC, Tourinho-Barbosa RR, de la Rosette J. Tumour microenvironment and focal therapy for prostate cancer. Curr Opin Urol 2022;32:248-53. [PMID: 35552306 DOI: 10.1097/MOU.0000000000000987] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Li L, Tao Z, Zhao Y, Li M, Zheng J, Li Z, Chen X. Prognostic Characteristics and Immune Effects of N6-Methyladenosine and 5-Methylcytosine-Related Regulatory Factors in Clear Cell Renal Cell Carcinoma. Front Genet 2022;13:864383. [DOI: 10.3389/fgene.2022.864383] [Reference Citation Analysis]
67 Chung DC, Jacquelot N, Ghaedi M, Warner K, Ohashi PS. Innate Lymphoid Cells: Role in Immune Regulation and Cancer. Cancers 2022;14:2071. [DOI: 10.3390/cancers14092071] [Reference Citation Analysis]
68 Chen S, Cheng J, Zhong Y, Liu R, Lu Z, Luo X. Liver-specific overexpression of Gab2 accelerates hepatocellular carcinoma progression by activating immunosuppression of myeloid-derived suppressor cells. Oncogene. [DOI: 10.1038/s41388-022-02298-7] [Reference Citation Analysis]
69 Guo Y, Xie Y, Luo Y. The Role of Long Non-Coding RNAs in the Tumor Immune Microenvironment. Front Immunol 2022;13:851004. [PMID: 35222443 DOI: 10.3389/fimmu.2022.851004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
70 von Amsberg G, Alsdorf W, Karagiannis P, Coym A, Kaune M, Werner S, Graefen M, Bokemeyer C, Merkens L, Dyshlovoy SA. Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel? Int J Mol Sci 2022;23:2569. [PMID: 35269712 DOI: 10.3390/ijms23052569] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
71 Jiang H, Yu D, Yang P, Guo R, Kong M, Gao Y, Yu X, Lu X, Fan X. Revealing the transcriptional heterogeneity of organ‐specific metastasis in human gastric cancer using single‐cell RNA Sequencing. Clinical & Translational Med 2022;12. [DOI: 10.1002/ctm2.730] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
72 Wieleba I, Wojas-Krawczyk K, Krawczyk P, Milanowski J. Clinical Application Perspectives of Lung Cancers 3D Tumor Microenvironment Models for In Vitro Cultures. Int J Mol Sci 2022;23:2261. [PMID: 35216378 DOI: 10.3390/ijms23042261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Lin M, Yang Z, Yang Y, Peng Y, Li J, Du Y, Sun Q, Gao D, Yuan Q, Zhou Y, Chen X, Qi X. CRISPR-based in situ engineering tumor cells to reprogram macrophages for effective cancer immunotherapy. Nano Today 2022;42:101359. [DOI: 10.1016/j.nantod.2021.101359] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
74 Wang L, Hu D, Xie B, Xie L. Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells. Invest New Drugs 2022. [PMID: 35089465 DOI: 10.1007/s10637-022-01218-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Tumino N, Besi F, Martini S, Di Pace AL, Munari E, Quatrini L, Pelosi A, Fiore PF, Fiscon G, Paci P, Scordamaglia F, Covesnon MG, Bogina G, Mingari MC, Moretta L, Vacca P. Polymorphonuclear Myeloid-Derived Suppressor Cells Are Abundant in Peripheral Blood of Cancer Patients and Suppress Natural Killer Cell Anti-Tumor Activity. Front Immunol 2022;12:803014. [DOI: 10.3389/fimmu.2021.803014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
76 Lin HJ, Liu Y, Lofland D, Lin J. Breast Cancer Tumor Microenvironment and Molecular Aberrations Hijack Tumoricidal Immunity. Cancers (Basel) 2022;14:285. [PMID: 35053449 DOI: 10.3390/cancers14020285] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
77 Siddiqui S, Glauben R. Fatty Acid Metabolism in Myeloid-Derived Suppressor Cells and Tumor-Associated Macrophages: Key Factor in Cancer Immune Evasion. Cancers (Basel) 2022;14:250. [PMID: 35008414 DOI: 10.3390/cancers14010250] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
78 Maria Teresa Palano, Matteo Gallazzi, Martina Cucchiara, Federico Dehò, Paolo Capogrosso, Antonino Bruno, Lorenzo Mortara. The tumor innate immune microenvironment in prostate cancer: an overview of soluble factors and cellular effectors. Explor Target Antitumor Ther 2022;3. [PMID: 36338516 DOI: 10.37349/etat.2022.00108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Mallaiah D, Vadde R. Role of Nano-immunotherapy in Colorectal Cancer: An Updated Review. Colon Cancer Diagnosis and Therapy Vol. 3 2022. [DOI: 10.1007/978-3-030-72702-4_5] [Reference Citation Analysis]
80 Shen H, Zhang Y, Kramer ED, Katsuta E, Wan Y, Chen Y, Wang J, Zhang Y, Matsuzaki J, Frangou C, Abrams SI, Zhang J. Loss-of-function of the hippo transducer TAZ reduces mammary tumor growth through a myeloid-derived suppressor cell-dependent mechanism. Cancer Gene Ther 2022;29:1791-800. [PMID: 35840667 DOI: 10.1038/s41417-022-00502-0] [Reference Citation Analysis]
81 Bline K, Andrews A, Moore-Clingenpeel M, Mertz S, Ye F, Best V, Sayegh R, Tomatis-Souverbielle C, Quintero AM, Maynard Z, Glowinski R, Mejias A, Ramilo O. Myeloid-Derived Suppressor Cells and Clinical Outcomes in Children With COVID-19. Front Pediatr 2022;10:893045. [PMID: 35733812 DOI: 10.3389/fped.2022.893045] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Vallejo-ardila DL, Parra-medina R, Combita A, Cardona AF, Paquet-fifield S. The Effects of Angiotensin-Converting Enzyme Inhibitors on Metastasis-Associated Myeloid Cells. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_91] [Reference Citation Analysis]
83 Malara N. Predictive and On-Treatment Monitoring Role of Circulating Biomarkers in Immuno-oncology. Handbook of Cancer and Immunology 2022. [DOI: 10.1007/978-3-030-80962-1_130-1] [Reference Citation Analysis]
84 Wei C, Ma Y, Wang F, Liao Y, Chen Y, Zhao B, Zhao Q, Wang D, Tang D. Igniting Hope for Tumor Immunotherapy: Promoting the “Hot and Cold” Tumor Transition. Clin Med Insights Oncol 2022;16:117955492211207. [DOI: 10.1177/11795549221120708] [Reference Citation Analysis]
85 Raineri D, Cappellano G, Vilardo B, Maione F, Clemente N, Canciani E, Boggio E, Gigliotti CL, Monge C, Dianzani C, Boldorini R, Dianzani U, Chiocchetti A. Inducible T-Cell Costimulator Ligand Plays a Dual Role in Melanoma Metastasis upon Binding to Osteopontin or Inducible T-Cell Costimulator. Biomedicines 2022;10:51. [DOI: 10.3390/biomedicines10010051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
86 Boral B, Ballı HT, Sözütok S, Pehlivan UA, Aikimbaev K. Clinical and prognostic significance of CD14 (+) HLA-DR (-/low) myeloid-derived suppressor cells in patients with hepatocellular carcinoma received transarterial radioembolization with Yttrium-90. Scand J Immunol 2021;:e13132. [PMID: 34936119 DOI: 10.1111/sji.13132] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
87 Datsi A, Sorg RV. Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End. Front Immunol 2021;12:770390. [PMID: 34795675 DOI: 10.3389/fimmu.2021.770390] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
88 Adams R, Moser B, Karagiannis SN, Lacy KE. Chemokine Pathways in Cutaneous Melanoma: Their Modulation by Cancer and Exploitation by the Clinician. Cancers (Basel) 2021;13:5625. [PMID: 34830780 DOI: 10.3390/cancers13225625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
89 Hao Z, Li R, Wang Y, Li S, Hong Z, Han Z. Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy. Biomark Res 2021;9:77. [PMID: 34689842 DOI: 10.1186/s40364-021-00333-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
90 Koushki K, Salemi M, Miri SM, Arjeini Y, Keshavarz M, Ghaemi A. Role of myeloid-derived suppressor cells in viral respiratory infections; Hints for discovering therapeutic targets for COVID-19. Biomed Pharmacother 2021;144:112346. [PMID: 34678727 DOI: 10.1016/j.biopha.2021.112346] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
91 Kapor S, Vukotić M, Subotički T, Đikić D, Mitrović Ajtić O, Radojković M, Čokić VP, Santibanez JF. Hydroxyurea Induces Bone Marrow Mesenchymal Stromal Cells Senescence and Modifies Cell Functionality In Vitro. J Pers Med 2021;11:1048. [PMID: 34834400 DOI: 10.3390/jpm11111048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Subudhi SK, Siddiqui BA, Aparicio AM, Yadav SS, Basu S, Chen H, Jindal S, Tidwell RSS, Varma A, Logothetis CJ, Allison JP, Corn PG, Sharma P. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. J Immunother Cancer 2021;9:e002919. [PMID: 34663638 DOI: 10.1136/jitc-2021-002919] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
93 Carter JM, Polley MC, Leon-Ferre RA, Sinnwell J, Thompson KJ, Wang X, Ma Y, Zahrieh D, Kachergus JM, Solanki M, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Thompson EA, Goetz MP. Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer. Clin Cancer Res 2021;27:5628-37. [PMID: 34108182 DOI: 10.1158/1078-0432.CCR-21-0343] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
94 Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, Shu P, Li D, Wang Y. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther 2021;6:362. [PMID: 34620838 DOI: 10.1038/s41392-021-00670-9] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 32.0] [Reference Citation Analysis]
95 Bayik D, Bartels CF, Lovrenert K, Watson DC, Zhang D, Kay K, Lauko A, Johnson S, Lo A, Mcgraw M, Grabowski M, Mohammadi AM, Veglia F, Fan Y, Vogelbaum MA, Scacheri P, Lathia JD. Distinct cell adhesion signature defines glioblastoma myeloid-derived suppressor cell subsets.. [DOI: 10.1101/2021.09.27.461995] [Reference Citation Analysis]
96 Qiu H, Shao Z, Wen X, Jiang J, Ma Q, Wang Y, Huang L, Ding X, Zhang L. TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy. Front Immunol 2021;12:716710. [PMID: 34539652 DOI: 10.3389/fimmu.2021.716710] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
97 Ugai T, Väyrynen JP, Lau MC, Borowsky J, Akimoto N, Väyrynen SA, Zhao M, Zhong R, Haruki K, Dias Costa A, Fujiyoshi K, Arima K, Wu K, Chan AT, Cao Y, Song M, Fuchs CS, Wang M, Lennerz JK, Ng K, Meyerhardt JA, Giannakis M, Nowak JA, Ogino S. Immune cell profiles in the tumor microenvironment of early-onset, intermediate-onset, and later-onset colorectal cancer. Cancer Immunol Immunother 2021. [PMID: 34529108 DOI: 10.1007/s00262-021-03056-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
98 Fu X, He Y, Li M, Huang Z, Najafi M. Targeting of the tumor microenvironment by curcumin. Biofactors 2021. [PMID: 34375483 DOI: 10.1002/biof.1776] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
99 Dai X, Ren L, Liu M, Cai H, Zhang H, Gong Q, Gu Z, Luo K. Nanomedicines modulating myeloid-derived suppressor cells for improving cancer immunotherapy. Nano Today 2021;39:101163. [DOI: 10.1016/j.nantod.2021.101163] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
100 Osei-Bordom DC, Kamarajah S, Christou N. Colorectal Cancer, Liver Metastases and Biotherapies. Biomedicines 2021;9:894. [PMID: 34440099 DOI: 10.3390/biomedicines9080894] [Reference Citation Analysis]
101 Wang J, Liu Y, Zhang S. Prognostic and immunological value of ATP6AP1 in breast cancer: implications for SARS-CoV-2. Aging (Albany NY) 2021;13:16904-21. [PMID: 34228637 DOI: 10.18632/aging.203229] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
102 Nascimento C, Ferreira F. Tumor microenvironment of human breast cancer, and feline mammary carcinoma as a potential study model. Biochim Biophys Acta Rev Cancer 2021;1876:188587. [PMID: 34237352 DOI: 10.1016/j.bbcan.2021.188587] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
103 Kapor S, Santibanez JF. Myeloid-Derived Suppressor Cells and Mesenchymal Stem/Stromal Cells in Myeloid Malignancies. J Clin Med 2021;10:2788. [PMID: 34202907 DOI: 10.3390/jcm10132788] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
104 Mu Q, Najafi M. Resveratrol for targeting the tumor microenvironment and its interactions with cancer cells. Int Immunopharmacol 2021;98:107895. [PMID: 34171623 DOI: 10.1016/j.intimp.2021.107895] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
105 Ye Z, Zou S, Niu Z, Xu Z, Hu Y. A Novel Risk Model Based on Lipid Metabolism-Associated Genes Predicts Prognosis and Indicates Immune Microenvironment in Breast Cancer. Front Cell Dev Biol 2021;9:691676. [PMID: 34195202 DOI: 10.3389/fcell.2021.691676] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
106 Amodio V, Mauri G, Reilly NM, Sartore-Bianchi A, Siena S, Bardelli A, Germano G. Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. Cancers (Basel) 2021;13:2638. [PMID: 34072037 DOI: 10.3390/cancers13112638] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
107 Hibino S, Kawazoe T, Kasahara H, Itoh S, Ishimoto T, Sakata-Yanagimoto M, Taniguchi K. Inflammation-Induced Tumorigenesis and Metastasis. Int J Mol Sci 2021;22:5421. [PMID: 34063828 DOI: 10.3390/ijms22115421] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 13.0] [Reference Citation Analysis]
108 Werner LR, Gibson KA, Goodman ML, Helm DE, Walter KR, Holloran SM, Trinca GM, Hastings RC, Yang HH, Hu Y, Wei J, Lei G, Yang XY, Madan R, Molinolo AA, Markiewicz MA, Chalise P, Axelrod ML, Balko JM, Hunter KW, Hartman ZC, Lange CA, Hagan CR. Progesterone promotes immunomodulation and tumor development in the murine mammary gland. J Immunother Cancer 2021;9:e001710. [PMID: 33958486 DOI: 10.1136/jitc-2020-001710] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
109 Sultan M, Alghetaa H, Mohammed A, Abdulla OA, Wisniewski PJ, Singh N, Nagarkatti P, Nagarkatti M. The Endocannabinoid Anandamide Attenuates Acute Respiratory Distress Syndrome by Downregulating miRNA that Target Inflammatory Pathways. Front Pharmacol 2021;12:644281. [PMID: 33995054 DOI: 10.3389/fphar.2021.644281] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
110 Singh S, Xiao Z, Bavisi K, Roszik J, Melendez BD, Wang Z, Cantwell MJ, Davis RE, Lizee G, Hwu P, Neelapu SS, Overwijk WW, Singh M. IL-1α Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma. J Immunol 2021;206:1966-75. [PMID: 33722878 DOI: 10.4049/jimmunol.2000523] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
111 Gupta B, Kim JO. Recent progress in cancer immunotherapy approaches based on nanoparticle delivery devices. J Pharm Investig 2021;51:399-412. [DOI: 10.1007/s40005-021-00527-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
112 Cui C, Lan P, Fu L. The role of myeloid-derived suppressor cells in gastrointestinal cancer. Cancer Commun (Lond) 2021;41:442-71. [PMID: 33773092 DOI: 10.1002/cac2.12156] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
113 Ilié M, Lantéri E, Chamorey E, Thamphya B, Hamila M, Montaudié H, Picard-Gauci A, Gardrat S, Passeron T, Lassalle S, Long-Mira E, Cherfils-Vicini J, Gilson E, Hofman V, Hofman P. Association of TRF2 expression and myeloid-derived suppressor cells infiltration with clinical outcome of patients with cutaneous melanoma. Oncoimmunology 2021;10:1901446. [PMID: 33796413 DOI: 10.1080/2162402X.2021.1901446] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
114 Li X, Liu Y, Zheng S, Zhang T, Wu J, Sun Y, Zhang J, Liu G. Role of exosomes in the immune microenvironment of ovarian cancer. Oncol Lett 2021;21:377. [PMID: 33777201 DOI: 10.3892/ol.2021.12638] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
115 Meng L, He X, Hong Q, Qiao B, Zhang X, Wu B, Zhang X, Wei Y, Li J, Ye Z, Xiao Y. CCR4, CCR8, and P2RY14 as Prognostic Factors in Head and Neck Squamous Cell Carcinoma Are Involved in the Remodeling of the Tumor Microenvironment. Front Oncol 2021;11:618187. [PMID: 33692955 DOI: 10.3389/fonc.2021.618187] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
116 Alotaibi F, Vincent M, Min WP, Koropatnick J. Reduced CD5 on CD8+ T Cells in Tumors but Not Lymphoid Organs Is Associated With Increased Activation and Effector Function. Front Immunol 2020;11:584937. [PMID: 33584650 DOI: 10.3389/fimmu.2020.584937] [Reference Citation Analysis]
117 Baram T, Rubinstein-Achiasaf L, Ben-Yaakov H, Ben-Baruch A. Inflammation-Driven Breast Tumor Cell Plasticity: Stemness/EMT, Therapy Resistance and Dormancy. Front Oncol 2020;10:614468. [PMID: 33585241 DOI: 10.3389/fonc.2020.614468] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
118 Blanter M, Gouwy M, Struyf S. Studying Neutrophil Function in vitro: Cell Models and Environmental Factors. J Inflamm Res 2021;14:141-62. [PMID: 33505167 DOI: 10.2147/JIR.S284941] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
119 MacDonald C, Ministero S, Pandey M, Robinson D, Forti Hong E, Hylander B, McCarthy P, Gordon C, Repasky E, Mohammadpour H. Comparing thermal stress reduction strategies that influence MDSC accumulation in tumor bearing mice. Cell Immunol 2021;361:104285. [PMID: 33484943 DOI: 10.1016/j.cellimm.2021.104285] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
120 Haist M, Stege H, Grabbe S, Bros M. The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment. Cancers (Basel) 2021;13:E210. [PMID: 33430105 DOI: 10.3390/cancers13020210] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 17.5] [Reference Citation Analysis]
121 Abrams SI. Developmental pathways of myeloid-derived suppressor cells in neoplasia. Cell Immunol 2021;360:104261. [PMID: 33373817 DOI: 10.1016/j.cellimm.2020.104261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
122 Hack SP, Zhu AX, Wang Y. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. Front Immunol 2020;11:598877. [PMID: 33250900 DOI: 10.3389/fimmu.2020.598877] [Cited by in Crossref: 48] [Cited by in F6Publishing: 54] [Article Influence: 16.0] [Reference Citation Analysis]
123 Moaaz M, Lotfy H, Elsherbini B, Motawea MA, Fadali G. TGF-β Enhances the Anti-inflammatory Effect of Tumor- Infiltrating CD33+11b+HLA-DR Myeloid-Derived Suppressor Cells in Gastric Cancer: A Possible Relation to MicroRNA-494. Asian Pac J Cancer Prev 2020;21:3393-403. [PMID: 33247701 DOI: 10.31557/APJCP.2020.21.11.3393] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
124 Shang J, Zha H, Sun Y. Phenotypes, Functions, and Clinical Relevance of Regulatory B Cells in Cancer. Front Immunol 2020;11:582657. [PMID: 33193391 DOI: 10.3389/fimmu.2020.582657] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]